BMS-626529 is a novel small-molecule attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4+ T-cells.
信号通路
Anti-infection
靶点
HIV
-
-
-
-
IC50
-
-
-
-
-
体外研究
BMS-626529 is a member of the new drug class of HIV-1 attachment inhibitors currently in development. BMS-663068 is the phosphonooxymethyl prodrug of BMS-626529, a novel small-molecule attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4(+) T cells. The activity of BMS-626529 is virus dependent, due to heterogeneity within gp120. Research result suggest that BMS-626529 should be active against the majority of HIV-1 viruses and support the continued clinical development of the compound.
体内研究
N/A
临床实验
N/A
特征
N/A
相关实验数据(此数据来自于公开文献,联迈生物并不保证其有效性):
酶活性检测实验
方法
N/A
细胞实验
细胞系
N/A
浓度
N/A
处理时间
N/A
方法
N/A
动物实验
动物模型
N/A
配制
N/A
剂量
N/A
给药方式
N/A
参考文献: 1. Nowicka-Sans, Beata; Gong, Yi-Fei; McAuliffe, Brian; et al. Antimicrobial Agents and Chemotherapy. 2012, 56(7), 3498-3507. 2. Charpentier, Charlotte; Larrouy, Lucile; Visseaux, Benoit et al. Journal of Antimicrobial Chemotherapy. 2012, 67(6), 1459-1461. 3. Nettles RE, Schürmann D, Zhu L et al. J Infect Dis. 2012 Oct 1, 206(7):1002-11. 包装清单: